Steris Plc SEC Filings

Martin Paul Edward, a director of STERIS plc (STE), reported equity awards on 08/08/2025: he received 1,407 nonqualified stock options with an exercise price of $242.85 and an expiration date of 08/08/2035. The filing states those options are fully vested and exercisable immediately. He also acquired 487 Career Restricted Stock Units (RSUs) that are fully vested and will be settled into ordinary shares six months after he ceases Board service. After these transactions the Form 4 lists 1,407 options and 4,562 RSUs as the amounts beneficially owned following the reported transactions. The form was signed by an authorized representative on 08/12/2025.

This disclosure is a routine Section 16 filing showing director compensation in equity form, with clear vesting and settlement mechanics described for the RSUs and immediate exercisability for the options.

Christopher S. Holland, a director of STERIS plc (STE), reported the acquisition of 975 Career Restricted Stock Units on 08/08/2025. The filing states these Career RSUs are fully vested immediately and each represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. Following the reported transaction, Mr. Holland beneficially owns 4,964 RSU-linked ordinary shares. The Form 4 was executed by an authorized representative on 08/12/2025.

In this Form 4 filing STERIS director Cynthia L. Feldmann reports a sale and new equity awards. On 08/11/2025 she sold 3,495 ordinary shares at a weighted-average price of $241.56, after which she holds 705 shares directly. The filing shows 8,663 ordinary shares held indirectly in the Cynthia L. Feldmann Revocable Trust. The report also records equity grants: on 08/08/2025 a director stock option to buy 1,407 shares at a $242.85 exercise price (exercisable immediately, expiring 08/08/2035) and 487 Career Restricted Stock Units that are fully vested and will be settled in ordinary shares six months after cessation of Board service. A director stock option with a $114.74 exercise price and 3,495 underlying shares is also listed with an exercisable date shown as 08/09/2028. The form is signed by an authorized representative on 08/12/2025.

Steris director Richard C. Breeden reported awards and grants dated 08/08/2025 in a Form 4 filing. The report shows the grant of 1,704 director stock options with an exercise price of $242.85 and an expiration date of 08/08/2035; the filing states these nonqualified stock options are fully vested and exercisable immediately. The filing also discloses 842 Career Restricted Stock Units (487 and 355 units) that are fully vested and will be settled in ordinary shares six months after the director ceases board service. Some awards were issued in lieu of fees ($25,000 for options and $86,000 for RSUs). Following the reported transactions, the reporting person beneficially owned 19,545 ordinary shares.

Alegria Esther M., a director of STERIS plc (STE), reported equity awards on Form 4 dated 08/08/2025. The filing shows an acquisition of 1,407 nonqualified stock options at an exercise price of $242.85 and 487 Career Restricted Stock Units (RSUs). The filing states the options are fully vested and exercisable immediately and carry an expiration date of 08/08/2035. Each Career RSU represents the right to one ordinary share and is fully vested but will be settled in shares six months after the director ceases Board service. The Form reports total beneficial ownership following these transactions of 2,896 ordinary shares and was signed by an authorized representative on 08/12/2025.

Karen L. Burton, VP & CAO and a company officer of STERIS plc (STE), reported a sale and an outstanding option in a Form 4 filing. On 08/11/2025 she sold 7,900 ordinary shares at a weighted average price of $241.73 per share (sales ranged from $241.33 to $242.32), reducing her direct beneficial ownership to 5,994 ordinary shares.

She continues to hold a fully vested employee stock option to purchase 7,900 ordinary shares at a strike price of $114.22 that originated from the company’s March 2019 redomiciliation exchange. Of the remaining shares, 3,216 are restricted and vest in scheduled tranches between October 1, 2025 and June 5, 2028.

Form 144 notice for STERIS plc (STE) shows a proposed sale of 3,781 ordinary shares executed through Charles Schwab with an aggregate market value of $914,084 and listing the shares outstanding as 98,490,606. The table indicates the shares were acquired and disposed on 08/12/2025 through an employee stock option exercise with the payment described as a broker payment for a cashless exercise. The filing also discloses a prior sale during the past three months: 4,110 shares sold on 08/11/2025 for $993,562. The notice includes the broker name and exchange (Charles Schwab & Co.; NYSE) and the mandatory representation that the seller is not aware of undisclosed material adverse information.

STERIS plc (STE) filed a Form 144 reporting a proposed sale of 4,110 ordinary shares through Charles Schwab & Co., Inc., with an aggregate market value of $993,562.00 and an approximate sale date of 08/11/2025. The filing shows the securities were acquired on 08/11/2025 via an employee stock option exercise and the payment was made through a broker cashless exercise.

The table lists the issuer's shares outstanding as 98,490,606. The filing also states there were no securities sold in the past three months by the person for whose account these securities are to be sold and includes the standard attestation that the filer is not aware of undisclosed material adverse information.

STERIS plc filed a Form 144 reporting a proposed sale of 4,110 ordinary shares to be executed on 08/11/2025 through Charles Schwab & Co., Inc. The filing lists an aggregate market value of $994,450 and shows 98,490,606 shares outstanding. The shares were acquired on 08/11/2025 via an employee stock option exercise and the payment method is recorded as a broker payment for a cashless exercise.

The notice states no securities were sold by the person in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.